Education, Conference Coverage and Articles
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
“Your brain thrives on connection; meeting people, interacting and sharing ideas is vital for not only your individual brain health but also our species survival” In this inspiring conversation, and as part of touchNEUROLOGY’s Future Leaders 2025 series, we speak ...
Watch leading experts discuss the use of neurofilament levels as a potential marker in ALS and SMA.
In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.
"I have learned to value meeting patients where they are, listening with empathy, and offering structure, which can build trust, strengthen compliance, and improve outcomes." Dr Anna Maria Laure, postgraduate trainee in psychiatry and psychotherapy at the Medical University ...
"it is great to find out that some reasoning and a prescription has helped someone turn their life around" Dr Alexander Lisinski, resident psychiatrist at Sahlgrenska University Hospital and researcher at the Department of Pharmacology, Sahlgrenska Academy, Gothenburg, Sweden, ...
Broadest approval to date in generalized myasthenia gravis The FDA approval of nipocalimab for generalized myasthenia gravis (gMG) introduces a targeted therapy within a validated class, offering the potential for durable disease control across the broadest patient population to date. ...
n this interview, we speak with Dr Anthony Caggiano, Chief Medical Officer and Head of R&D at Cognition Therapeutics, and Lisa Ricciardi, the company’s Chief Executive Officer. They discuss the design and findings of the phase II SHINE trial evaluating zervimesine (CT-1812) in mild to moderate Alzheimer’s disease, including important biomarker and clinical insights presented at recent international conferences. They also reflect on promising data from a study in dementia with Lewy bodies (DLB) and how these results are shaping the company’s next steps.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
"this is a field where rigorous science can rapidly change lives" Dr Bardia Nourbakhsh, Associate Professor of Neurology, Johns Hopkins University, Baltimore, MD, USA, is a rising star whose work bridges rigorous clinical neurological research with compassionate, patient-centred care. ...
Multiple sclerosis (MS) is a chronic neurological condition that often presents with vague or intermittent symptoms, making early recognition particularly challenging in primary care. As diagnostic delays can significantly impact long-term outcomes, timely identification and referral are critical. In alignment ...
In this Q&A, Dr Andy Liu, Associate Professor of Neurology at Duke University School of Medicine, discusses his presentation on the clinical use of lecanemab in Alzheimer’s disease. Drawing on real-world experience and findings from the 2022 CLARITY AD study, Dr Liu explores the treatment’s benefits, challenges in daily practice and the importance of patient-centred care in this evolving therapeutic landscape.
Watch a leading expert discuss the key signs and symptoms of Friedreich ataxia and how to avoid diagnostic delays.
Launching today, the world’s first multisector advocacy movement dedicated to stroke - the Global Stroke Action Coalition - has issued an urgent call to action to address growing inequities in stroke. Already a leading cause of death and disability, without intervention, the global burden of stroke is projected to rise by a further 50% over the next 25 years, claiming 100 million lives and costing US$1.6 trillion each year.
From 4–6 June 2025, the 20th International Forum on Mood and Anxiety Disorders (IFMAD) will take place in Budapest, Hungary, marking a significant milestone for this long-standing event in psychiatric research and practice. Since its inception in 1999, IFMAD has brought together global experts to explore the latest advances in the understanding and treatment of mood and anxiety disorders.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.